Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYTKNASDAQ:MLYSNASDAQ:PTCTNASDAQ:RYTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTKCytokinetics$34.54+4.3%$34.97$29.31▼$61.38$4.13B0.591.55 million shs2.01 million shsMLYSMineralys Therapeutics$16.03-1.0%$14.57$8.24▼$18.38$1.04B-0.17504,531 shs486,553 shsPTCTPTC Therapeutics$51.74+0.1%$46.50$28.72▼$58.38$4.10B0.51864,898 shs827,719 shsRYTMRhythm Pharmaceuticals$67.37+1.0%$61.45$39.46▼$69.89$4.29B2.3557,249 shs422,310 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTKCytokinetics+4.26%+7.94%+8.99%-21.48%-36.23%MLYSMineralys Therapeutics-0.99%-0.93%+9.42%+22.27%+18.74%PTCTPTC Therapeutics+0.10%+2.07%+16.98%-3.49%+37.57%RYTMRhythm Pharmaceuticals+0.97%+2.59%+17.43%+31.27%+64.28%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYTKCytokinetics4.0811 of 5 stars4.51.00.04.62.50.80.0MLYSMineralys Therapeutics2.7088 of 5 stars3.41.00.00.02.95.00.0PTCTPTC Therapeutics3.2195 of 5 stars3.31.00.04.41.80.80.0RYTMRhythm Pharmaceuticals3.8484 of 5 stars3.51.00.04.33.10.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYTKCytokinetics 2.93Moderate Buy$70.92105.34% UpsideMLYSMineralys Therapeutics 2.75Moderate Buy$38.00137.06% UpsidePTCTPTC Therapeutics 2.64Moderate Buy$63.7523.21% UpsideRYTMRhythm Pharmaceuticals 3.00Buy$76.6213.72% UpsideCurrent Analyst Ratings BreakdownLatest MLYS, CYTK, RYTM, and PTCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2025MLYSMineralys TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold6/9/2025CYTKCytokineticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$71.00 ➝ $53.005/29/2025CYTKCytokineticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$103.00 ➝ $84.005/29/2025RYTMRhythm PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$78.00 ➝ $94.005/27/2025PTCTPTC TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$68.00 ➝ $74.005/14/2025MLYSMineralys TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$48.005/14/2025CYTKCytokineticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.00 ➝ $72.005/13/2025CYTKCytokineticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.005/9/2025PTCTPTC TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$55.00 ➝ $68.005/8/2025CYTKCytokineticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$55.00 ➝ $53.00(Data available from 6/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYTKCytokinetics$19.22M214.64N/AN/A($3.94) per share-8.77MLYSMineralys TherapeuticsN/AN/AN/AN/A$3.84 per shareN/APTCTPTC Therapeutics$1.77B2.31$2.49 per share20.80($10.85) per share-4.77RYTMRhythm Pharmaceuticals$136.86M31.32N/AN/A$2.87 per share23.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYTKCytokinetics-$526.24M-$5.29N/AN/AN/A-17,906.25%N/A-50.21%8/6/2025 (Estimated)MLYSMineralys Therapeutics-$177.81M-$3.73N/AN/AN/AN/A-67.97%-62.40%8/12/2025 (Estimated)PTCTPTC Therapeutics-$626.60M$6.51N/AN/AN/A-50.32%N/A-16.44%8/6/2025 (Estimated)RYTMRhythm Pharmaceuticals-$184.68M-$2.81N/AN/AN/A-230.07%-367.36%-77.47%8/5/2025 (Estimated)Latest MLYS, CYTK, RYTM, and PTCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025MLYSMineralys Therapeutics-$1.02-$0.79+$0.23-$0.79N/AN/A5/7/2025Q1 2025RYTMRhythm Pharmaceuticals-$0.69-$0.81-$0.12-$0.81$40.43 million$37.72 million5/6/2025Q1 2025CYTKCytokinetics-$1.41-$1.36+$0.05-$1.36$2.77 million$1.60 million5/6/2025Q1 2025PTCTPTC Therapeutics$0.85$10.04+$9.19N/A$437.16 million$1.18 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYTKCytokineticsN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYTKCytokinetics5.939.289.28MLYSMineralys TherapeuticsN/A14.0214.02PTCTPTC TherapeuticsN/A2.102.04RYTMRhythm PharmaceuticalsN/A3.493.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYTKCytokineticsN/AMLYSMineralys Therapeutics84.46%PTCTPTC TherapeuticsN/ARYTMRhythm PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCYTKCytokinetics2.70%MLYSMineralys Therapeutics25.56%PTCTPTC Therapeutics5.50%RYTMRhythm Pharmaceuticals6.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYTKCytokinetics250119.43 million114.00 millionOptionableMLYSMineralys Therapeutics2865.18 million33.27 millionOptionablePTCTPTC Therapeutics1,41079.26 million72.88 millionOptionableRYTMRhythm Pharmaceuticals14063.62 million58.02 millionOptionableMLYS, CYTK, RYTM, and PTCT HeadlinesRecent News About These CompaniesRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells $478,459.55 in StockJune 10 at 5:47 PM | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Reaches New 1-Year High - Should You Buy?June 9 at 3:32 PM | marketbeat.comThe Rhythm Foundation seeks contract extension to continue programming at Miami Beach BandshellJune 7, 2025 | msn.comHeartbeats That Matter: The Silent Risks of Heart Rhythm DisordersJune 7, 2025 | deccanchronicle.comMillennium Management LLC Sells 21,718 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)June 7, 2025 | marketbeat.comJefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price TargetJune 5, 2025 | msn.comHere's How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 YearsJune 5, 2025 | benzinga.comHennion & Walsh Asset Management Inc. Has $4.75 Million Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)June 4, 2025 | marketbeat.com76,084 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Bought by Universal Beteiligungs und Servicegesellschaft mbHJune 2, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Holdings Cut by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCMay 31, 2025 | marketbeat.comStifel Nicolaus Raises Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $94.00May 30, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Trading Up 4.7% - Here's WhyMay 30, 2025 | marketbeat.comRhythm Pharmaceuticals (RYTM) Gets Price Target Upgrade by Stifel Amid Obesity Drug OptimismMay 30, 2025 | msn.com3RYTM : 12 Analysts Assess Rhythm Pharmaceuticals: What You Need To KnowMay 29, 2025 | benzinga.comRhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 4.1% - Should You Sell?May 29, 2025 | marketbeat.comFunds Go All In On Weight-Loss Leader; Stock Nears HighsMay 29, 2025 | investors.comAmeriprise Financial Inc. Purchases 11,480 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 29, 2025 | marketbeat.comVoloridge Investment Management LLC Purchases 27,214 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 25, 2025 | marketbeat.comProShare Advisors LLC Grows Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 25, 2025 | marketbeat.comDeutsche Bank AG Has $2.73 Million Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 24, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Position Trimmed by Frazier Life Sciences Management L.P.May 23, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMLYS, CYTK, RYTM, and PTCT Company DescriptionsCytokinetics NASDAQ:CYTK$34.54 +1.41 (+4.26%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$34.40 -0.14 (-0.39%) As of 06/10/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Mineralys Therapeutics NASDAQ:MLYS$16.03 -0.16 (-0.99%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$16.10 +0.07 (+0.44%) As of 06/10/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.PTC Therapeutics NASDAQ:PTCT$51.74 +0.05 (+0.10%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$51.44 -0.31 (-0.59%) As of 04:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Rhythm Pharmaceuticals NASDAQ:RYTM$67.37 +0.65 (+0.97%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$67.38 +0.00 (+0.01%) As of 06/10/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Stock Hits All-Time Highs: Smart Buy or FOMO Trap? These 3 Stocks Could Be Back in Play Before You Know It Casey’s Surges on Strong Q4, More Gains Likely Ahead Qualcomm: What Monday’s Jump Tells Us About the Stock's Prospects Government Mandate Sends eVTOL Stocks Flying AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway Meta Pulls Ahead of the Mag 7: Analysts Predict a Breakout Year ASML’s AI Edge: How Its EUV Tech Is Creating a New Monopoly Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
